Questcor Pharmaceuticals Initiates Quarterly Cash Dividend and Expands Stock
Repurchase Program
ANAHEIM, Calif., Sept. 28, 2012 /PRNewswire via COMTEX/ -- Questcor
Pharmaceuticals, Inc. (QCOR) today announced that its Board of Directors has
adopted a policy to pay a regular quarterly dividend in such amounts as the Board
of Directors may determine from time to time. The Board of Directors has declared
an initial quarterly cash dividend of $0.20 per share to all shareholders of
record at the close of business on October 31, 2012. The initial dividend will be
paid on or about November 15, 2012. Future dividends will be at the discretion of
the Board of Directors.
Questcor also announced that its Board of Directors has increased the Company's
common stock repurchase program to 7 million shares. This includes the 3.2
million shares that were remaining under the prior authorization. Repurchases
under the program may be made in the open market or in privately negotiated
transactions from time to time in compliance with Securities and Exchange
Commission regulations, depending on market conditions and other factors.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor's primary product is H.P. Acthar? Gel
(repository corticotropin injection), an injectable drug that is approved by the
FDA for the treatment of 19 indications. Of these 19 indications, Questcor
currently generates substantially all of its net sales from three indications:
the treatment of proteinuria in idiopathic types of nephrotic syndrome, the
treatment of acute exacerbations of multiple sclerosis in adults, and the
treatment of infantile spasms in children under two years of age. With respect to
nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a
remission of proteinuria in the nephrotic syndrome without uremia of the
idiopathic type or that due to lupus erythematosus." Questcor has also launched a
pilot effort in rheumatology, as Acthar is approved for several
rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus
and Rheumatoid Arthritis. Questcor is also exploring the possibility of
developing markets for other on-label indications and the possibility of pursuing
FDA approval of additional indications not currently on the Acthar label where
there is high unmet medical need. For more information about Questcor, please
visit questcor.com.
Note: Except for the historical information contained herein, this press release
contains forward-looking statements that have been made pursuant to the Private
Securities Litigation Reform Act of 1995. These statements relate to future
events or our future financial performance. In some cases, you can identify
forward-looking statements by terminology such as "believes," "continue,"
"could," "estimates," "expects," "growth," "may," "plans," "potential," "should,"
"substantial" or "will" or the negative of such terms and other comparable
terminology. These statements are only predictions. Actual events or results may
differ materially. Factors that could cause or contribute to such differences
include, but are not limited to, the following:
Our reliance on Acthar for substantially all of our net sales and profits;
Our ability to continue to generate revenue from sales of Acthar to treat
on-label indications associated with Nephrotic Syndrome, and our ability to
develop other therapeutic uses for Acthar;
Research and development risks and our reliance on third-parties to conduct
research and development and the ability of research and development to generate
successful results;
Our ability to receive high reimbursement levels from third party payers;
Our ability to comply with federal and state regulations, including regulations
relating to pharmaceutical sales and marketing practices;
Regulatory changes or other policy actions by governmental authorities and other
third parties in connection with U.S. health care reform or efforts to reduce
federal and state government deficits;
An increase in the proportion of our Acthar unit sales comprised of
Medicaid-eligible patients and government entities;
Our ability to effectively manage our growth, including the expansion of our
sales force, and our reliance on key personnel;
Volatility in Questcor's monthly and quarterly Acthar shipments, estimated
channel inventory, and end-user demand, as well as volatility in our stock price;
and
Other risks discussed in Questcor's annual report on Form 10-K for the year ended
December 31, 2011 as filed with the Securities and Exchange Commission, or SEC,
on February 22, 2012, and other documents filed with the SEC. The risk factors
and other information contained in these documents should be considered in
evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions
to these forward-looking statements, which may be made to reflect events or
circumstances after the date of this release.
For more information, please visit questcor.com or
acthar.com.
SOURCE Questcor Pharmaceuticals, Inc. |
